Research progress in liver targeted therapy for nonalcoholic fatty liver disease
10.3969/j.issn.1001-5256.2014.05.024
- VernacularTitle:非酒精性脂肪性肝病的靶向治疗研究进展
- Author:
Xueyuan JIN
;
Huifen WANG
- Publication Type:Journal Article
- Keywords:
fatty liver;
fatty acid bile acid conjugates;
ursodeoxycholyl lysophosphatidylethanolamide;
review
- From:
Journal of Clinical Hepatology
2014;31(5):469-472
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic fatty liver disease (NAFLD)is the most common progressive liver disease worldwide.Currently,there is no satisfy-ing treatment for NAFLD.Research progress in fatty acid bile acid conjugates (FABACs)and ursodeoxycholyl lysophosphatidylethanolamide (UDCA-LPE),which are two novel liver targeted drugs with anti-NAFLD effects,is reviewed.FABACs,which reduce liver fat in pa-tients with NAFLD induced by high-fat diet by regulating lipid metabolism,have been proved effective in preventing and treating NAFLD. The safety and efficacy of FABACs in NAFLD patients have been confirmed in a phase II,randomized,double-blind,placebo-controlled trial.UDCA-LPE can not only reduce liver fat in NAFLD patients,but also inhibit mitochondrial damage and apoptosis and promote hepa-tocyte regeneration,with a marked anti-inflammatory effect during the development of NAFLD.Therefore,FABACs and UDCA-LPE hold promise for preventing and treating NAFLD.
